Earth Science Tech Inc. (ETST)

[Cheds]

Doral, FL, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, has signed an agreement with Axcelon Biopolymers Corp for the exclusive distribution of their Nanoderm™ Biopolymer products in Morocco and Djibouti, which was hinted in the beginning of August.

NanodermTM is a unique wound care product, which is used by hospitals, clinics, and the general public for a variety of wound treatments, including burns, scratches, and more serious wounds like diabetic foot ulcers. It is also excellent for soldiers during missions. Unlike regular bandages, Nanoderm™ is applied only once over most wounds, where it remains for the duration of the healing process. It provides a barrier to infections, while allowing air to pass through. This promotes healing and reduces pain. For these reasons, active consumers and travelers enjoy the flexibility of the treatment.

As the exclusive distributor in the two mentioned countries, ETST will be marketing two medical devices at the same time; the MSN-2 medical device for STI testing and the Nanoderm™ product.

“We are very proud to launch Nanoderm™ products in countries where we are planning to introduce our innovative MSN-2 medical device through Earth Science Pharmaceutical, Inc.,” said CEO & CSO, Dr. Michel Aubé, “This will allow for the development of cost-sharing promotion plans. Axcelon products are already certified for sale among Canada and many other countries. We are working to expand the distribution exclusivities mostly in already industrialized countries”

View Nanoderm’s website for more information on the product.

Advances in MSN-2 Project, New Canadian filial created

ETST has officially created a new filial company, Canna Inno Laboratories, Inc., which will be instrumental in the research and testing needed to bring new and innovative nutraceutical products to market. Many of the partners who are involved in the final testing and process development for the ETST nutraceutical products already in the pipeline are located in Québec, Canada. As a Canadian company, the new subsidiary will be better placed to work with local governments in Québec to ensure that the work meets standards as well as receiving grants for further studies.

In other news, ETST has found a clinic in Québec to conduct pre-launch testing of the MSN-2. The name of the clinic specialized in meeting the needs of at-risk youth and youth in difficulty will be announced soon. As STI are a significant problem for this demographic, the clinic is well-positioned to conduct testing of the MSN-2. In a short period of time we will help many young women in difficulty escape the serious consequences of an untreated STI.

Nickolas S. Tabraue, ETST’s President, Director, & COO concluded with, “Earth Science Tech is lining up to truly be a leading biotech company as we partner up with innovative companies and diversify solutions to help with many common conditions. We have many exciting announcements and updates on our patents, KannaBidioiD subsidiary, distribution, education strategy, and expansion I look forward on sharing very soon.”





https://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech--Inc--Announces-New-Agreement-with-Axcelon-Biopolymers-Corp--for-Distribution-of-Nanoderm-trade--Medical-Device--amp--Advances-with-Its-MSN-2-Medical-Device?id=170151&b=y